Ebola response turns to Merck vaccine, Gilead drug as Congo outbreak worsens
Merck & Co.’s Ebola vaccine and an antiviral drug from Gilead Sciences Inc. are set for wider use in eastern Democratic Republic of Congo to blunt the fastest-growing Ebola outbreak on record. The Africa Centres for Disease Control and Prevention and Congolese officials plan to expand access to both products across two provinces as the epidemic outpaces conventional control measures. Almost ...